ADMA earnings date and last-quarter result: last quarter beat, P/E 12.14. Updated 2026-07-23.
ADMA Biologics (ADMA) Research Hub
ADMA Biologics (ADMA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 11.07 USD (+3.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 12.14, market cap 1.95B. This hub links to the full technical, earnings and options research available for ADMA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.07 USD (+3.65%) |
| 52-week range | 8.16 USD – 11.33 USD |
| Trend regime | Range |
| 14-day RSI | 67.6 (Bullish) |
| Trailing P/E | 12.14 |
| Market cap | 1.95B |
| Dividend yield | 0.00% |
Available research for ADMA
Covered Call on ADMA: how it works, illustrative setup around the real 11.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADMA: how it works, illustrative setup around the real 11.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADMA: how it works, illustrative setup around the real 11.07 USD price, max profit/loss, breakeven and when to use it. Educational.
ADMA technical analysis: range, last 11.07 USD, RSI 67.6, 52w range 8.16 USD–11.33 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ADMA in?
ADMA Biologics (ADMA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ADMA in an uptrend or downtrend?
As of 2026-10-26, ADMA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADMA's trailing P/E ratio?
ADMA's trailing P/E is 12.14, with a market cap of 1.95B. See the earnings research page for full valuation detail.